A first-of-its-kind inhalable gene therapy for lung cancer that genetically modifies people’s lung cells has been fast-tracked towards potential approval after promising clinical trial results. “Very ...

Eli Lilly is continuing a run of dealmaking to strengthen its genetic medicine offering by penning a pact with gene editing company Seamless Therapeutics. This morning’s deal with Seamless centers on ...

TULSA, Okla. — Public Service Company of Oklahoma has activated its storm management processes and positioned over 1,000 workers strategically across the state as a winter storm approaches the region.

In 2018, a nervous-looking He Jiankui took the stage at a scientific conference in Hong Kong. A hush settled over the packed auditorium as the soft-spoken Chinese scientist adjusted his microphone and ...

The Oklahoma Corporation Commission approves PSO’s request to purchase a power plant in Jenks. PSO first asked OCC to buy the Green Country Power Plant from Tokyo-based J-Power back in September. The ...

Here’s how extinct DNA could help us in the present—and the future. Yeah, we know—it’s not a dire wolf. In early 2025, the Texas biotech company Colossal Biosciences landed with a splash on the cover ...

Forbes contributors publish independent expert analyses and insights. A patient in a late-stage gene editing trial for a rare heart condition died from fatal liver complications after receiving an ...

OKLAHOMA — Public Service Company of Oklahoma (PSO) has filed a rate review with the Oklahoma Corporation Commission that would lead to a rate increase for residential customers. If the request is ...

There is no cure for the rare disease Hereditary Spastic Paraplegia (HSP), but researchers from Drexel University’s College of Medicine and the UMass Chan Medical School have achieved ...

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...

Revolutions in gene therapy are rapidly changing the landscape of modern medicine. Revolutions in gene therapy are rapidly changing the landscape of modern medicine, forcing society and science alike ...

Regeneron is adding its name to Tessera Therapeutics’ unique in vivo gene-writing program, inking a deal that lets it in on a prospect for alpha-1 antitrypsin deficiency (AATD) through a $150 million ...